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Abstract
We aimed to investigate the determinants of optimal highly active antiretroviral therapy (HAART)
adherence and time interval between successive clinic visits, as well as the association between
these two processes. This was done by reviewing routinely collected patient information in the
Centre for the AIDS Programme of Research in South Africa (CAPRISA). Records of 688 patients
enrolled in the CAPRISA AIDS treatment (CAT) programme between 2004 and 2006 were
analysed. Patients were considered adherent if they had taken at least 95% of their prescribed
drugs. The adherence has been measured using the pill counts data. A multivariate generalized
mixed random effects approach was used to jointly analyse optimal HAART adherence and time
interval between successive visits. The results showed that on the overall, the association between
optimal HAART adherence and time interval between successive visits was negative. The results
further showed that the interaction between time and treatment site had a significant joint effect on
optimal HAART adherence and time interval between successive visits. The interaction revealed
that as the number of follow-up visits increased, the interval between successive visits also
increased while at the same time high levels of optimal adherence were maintained in the rural
treatment site. Moreover, after accounting for the time interval between successive visits, the
results showed that optimal HAART adherence was significantly associated with having a cell
phone, living with a partner as well as interactions that include time and gender, time and
treatment site, age and gender and age and education. The findings provide evidence of a negative
association between optimal HAART adherence and the time interval between successive clinic
visits on the overall, which therefore indicates that longer time interval between successive clinic
visits is undesirable if optimal HAART adherence is to be maintained. This notwithstanding, rural
patients were able to maintain HAART adherence for longer time interval between successive
clinic visits. Furthermore, the findings indicated that optimal HAART adherence was low for
some sub-populations, such as the urban and male populations, thus vigorous ongoing adherence
counseling is required.
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The introduction of highly active antiretroviral therapy (HAART) has produced a
remarkable decrease in HIV morbidity and mortality (Mocroft et al., 2003). The success of
HAART relies on high levels of sustained medication adherence in order to maximize its
clinical effectiveness (Bangsberg et al., 2001). Strict adherence is fundamental to achieving
viral suppression, avoiding viral rebound, increasing levels of CD4 cell counts and
minimizing both the potential risks associated with the development of drug resistance and
the risk of death (Bangsberg et al., 2003). Patients who take 95% or more of their prescribed
medication benefit more from treatment than those who take less than 95% (Paterson et al.,
2000). As HIV cannot be eradicated, it is likely that people on antiretroviral therapy (ART)
will need to take antiretroviral drugs for the foreseeable future (Cambiano et al., 2010). This
coupled with rapidly expanding access to antiretroviral drugs in resource-poor settings, it is
vital to closely monitor whether patients are able to maintain HAART adherence over time
and identify predictors of long-term adherence in order to develop interventions that can
encourage sustained high levels of adherence.
A related process to strict adherence to medication is regular adherence to clinic attendance.
Most patients on ART are scheduled to attend a health facility monthly for a clinical
examination, laboratory examination if needed and to refill their ARV drugs (Seguy et al.,
2007). It has been shown that inconsistency in clinic attendance is a potential risk for poor
adherence to medication (Ross-Degnan et al., 2010). Studies have revealed that a greater
number of total elapsed days between missed visit and the next visit, as well as a greater
number of missed clinic appointments were risk factors for virological failure in HIV-
infected patients receiving HAART (Lucas, Chaisson & Moore, 1999). Thus, jointly
modeling HAART adherence and time that elapse between successive visits can reveal a
great deal of insight about factors that influence behaviour change of patients.
Under the assumption that the time interval between one clinic visit to the next is the same
across all follow-up visits, it was established that social, demographic, behavioural,
economic and clinical factors affect optimal HAART adherence over time (Maqutu,
Zewotir, North, Naidoo & Grobler, 2010a). The assumption of equal time interval between
successive visits to the clinic is a commonly made assumption in longitudinal studies
exploring factors associated with long-term adherence in Sub-Saharan Africa (see for
example (Byakika-Tusiime et al., 2005; Etard et al., 2007; Maqutu et al., 2010a)). In reality,
however, this assumption of equal interval between successive visits might not necessarily
hold because at times patients are unable to keep their scheduled clinic appointments for
various reasons; they either make an early or a late visit to the clinic. Studies that evaluate
factors influencing HAART adherence taking into account the time interval between
successive visits are limited in the literature, hence the motivation for this study. To this end,
there are no studies that assess and provide an empirical evidence of the association between
optimal HAART adherence over time and time interval between successive visits. We
therefore aim to investigate social, demographic, behavioural, economic and clinical factors
that jointly affect both optimal HAART adherence status of patients and time interval
between successive visits. And in the process, we seek to assess whether the explanatory
variables that were found to be significantly related with optimal HAART adherence in the
previous study (Maqutu et al., 2010a) would still have a significant effect on long-term
optimal HAART adherence even when time interval between successive clinic visits was
accounted for. Also evaluating the association between the optimal HAART adherence and
time interval between successive clinic visits was of interest.
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The data used in this study are secondary data obtained from the Centre for the AIDS
Programme of Research in South Africa (CAPRISA). CAPRISA started a HAART rollout
program in 2004. The CAPRISA AIDS Treatment (CAT) Programme offers HIV care
services at two sites in KwaZulu-Natal, South Africa, namely the eThekwini Clinical
Research site (urban site), and the Vulindlela Clinical Research site (rural site). The
programme started providing free HAART through a President’s Emergency Plan for AIDS
Relief (PEPfAR) grant at a time when access to HAART in the public sector was limited.
Adult patients with a CD4+ count below 200 cells/μL, or patients with World Health
Organisation (WHO) stage 4 of the HIV disease, were eligible for HAART initiation. Prior
to HAART initiation, all patients received three sessions of adherence education, motivation
and preparedness training.
Patients visited the treatment sites monthly to collect their treatment and to undergo a
clinical examination. All patients were on regimens containing two nucleoside reverse
transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. Patient
information was recorded on data collection sheets at the clinics; it underwent two levels of
quality control, and was faxed to a central data management centre. The secondary data
analysed in this study consisted of a retrospective review of patients’ records in the CAT
programme between June 2004 and September 2006. Only patients with pill count data for
the initial visit, and at least one other clinic visit for the defined study period, were included
in the analysis. The number of follow-up visits differed per patient, as some patients started
treatment earlier and therefore had more visits, while some patients dropped out of the
treatment programme prematurely. Approval for the data collection and analysis was
obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee
Variables of interest
Outcome variables—The first outcome variable was optimal adherence to HAART,
which has been measured using the pill counts data. Pill counts data were recorded by the
pharmacist at every patient’s visit to the clinic, thus enabling the measurement of adherence
at every visit. Patients were classified as optimally adherent if they took at least 95% of the
prescribed drugs in a given regimen (Paterson et al., 2000) otherwise, they were considered
non-adherent. The second outcome variable was time interval which was measured as the
number of days between successive visits for each patient.
Independent covariates—Baseline demographic and socio-economic variables included
age (in years), gender, educational status, treatment site, whether or not a patient lived with a
partner, whether or not the patient was a source of household income, access to tap water
and electricity, and whether a patient owned a cell phone. Other variables recorded at
baseline and included were World Health Organization (WHO) HIV stages, CD4 cell count
(cells/μL), weight (kilograms), whether or not a patient was optimally adherent at baseline.
Patients were asked why they did an HIV test and their responses included being unwell,
testing for no specific reason, testing because a partner died of HIV, being ill and
unfaithfulness. Reason for testing was therefore classified as possible exposure to HIV, no
specific reason and unwell.
Time was measured as a continuous variable representing monthly follow-up visits to the
treatment site. The variable time starts with the value 1 for the first follow-up visit, 2 for the
second visit, up to 17 for the seventeenth follow-up visit. Weight was measured at every
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follow-up visit and was modeled as a time-varying covariate. Additional details of the study
design and some of the variables can be obtained from Maqutu et al. (2010a; 2010b).
Statistical analysis
Socio-demographic and clinical characteristics of the study population were summarized
using the mean and standard deviation (SD) as well as the median and inter-quartile range
(IQR) while for categorical variables proportions were used.
The optimal adherence outcome was modeled as a binary variable that follows Bernoulli
distribution while time interval between successive visits outcome was modeled as a non-
negative variable that follows a Gamma distribution. We formulated a joint model for both
outcomes through a multivariate generalized mixed model approach. In this case, the
bivariate joint distribution of both outcomes is specified by assuming a general form of a
mixed model where the residual error structure and the link function are allowed to change
with the nature of the various outcomes (Molenberghs & Verbeke, 2005). Because our
primary interest was in assessing the joint effect of the predictor variables at the population
level, a joint marginal model was fitted where the association between the two outcomes at
each time point as well as the association emerging from the longitudinal structure of the
data is treated as a nuisance parameter that had to be accounted for.
To evaluate the association between the optimal HAART adherence and time interval
between successive visits, a conditional random-intercepts model was fitted. In this model,
the correlation between the two outcomes as well as the correlation coming from the
longitudinal structure of the data is specified through the random effects structure
(Gueorguieva, 2001). In our case, it was done by assuming separate random intercepts for
each outcome variable and then combining them by imposing a joint multivariate
distribution on the random intercepts.
All statistical tests were conducted at a 5% level of significance and analyses were done
using SAS (version 9.1.3).
Results
Baseline socio-demographic and clinical characteristics of patients
The baseline socio-demographic and clinical characteristics of patients included in the
analysis are presented in Table 1. A total of 688 patients, 369 (54%) from the urban site and
319 (46%) from the rural site were included in the analysis. The mean age of patients was
34.1 years (standard deviation (SD) = 8.2 years), 70% were male and 75% were not living
with a partner. Most of the patients had attained secondary or higher level of education
(69%), and 28% of patients were classified as sources of their household income. Over 90%
of the patients stayed in households that had access to tap water and electricity, while 42%
of the households had cell phones. The average baseline weight was 61.4kg (SD = 13.0kg),
mean CD4+ cell count of 107.5 cells/μL (SD=64.2 cells/ μL) and 64% of patients were
classified as WHO stage 3. Over half of the patients (56%) reported to have taken an HIV
test as they were not well, while 26% reported no specific reason for testing and 18% took
an HIV test as they were concerned that they had been exposed to HIV. In the initial month
of treatment, 79% of the patients were at least 95% adherent to HAART. The number of
follow-up visits ranged between 2 and 17 per patient, with the median of 8 (IQR: 5-12). The
median of time interval between successive visits is 28 days (IQR: 26-30). Optimal
adherence has been increasing over the follow-up visits (Figure 1). The proportion of
patients who were at least 95% adherent (optimally adherent) to HAART increased from
58% at the first follow-up visit to 86% at the last follow-up visit. Detailed discussions of the
baseline characteristics can also be found from Maqutu et al., (2010a).
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The results showed that the interaction of time and treatment site had a significant joint
effect on both optimal HAART adherence and time interval between successive visits (Table
2). Both outcomes increased as the number of follow-up visits increased, however, the rate
at which they increased differed depending on whether a patient attended a rural or urban
treatment site. The rate at which optimal adherence increased over time in the rural site was
higher compared to the urban site [aOR = 1.06, P=0.0002] while at the same time as the
number of follow-up visits increased, the expected time interval between successive visits
was likely to increase in the rural site compared to the urban treatment site [aOR=1.007,
P=0.0003].
The results further showed that after accounting for the time interval between successive
visits, optimal HAART adherence was significantly higher when patients had cell phones
[adjusted odds ratio (aOR) = 1.269, P = 0.001] and when they lived with a partner [aOR =
1.347, P = 0.002]. Moreover, the results showed that optimal HAART adherence increased
on average over time, however, the rate of increase differed by gender [aOR = 1.074,
P<0.0001] in favour of females and reason for taking an HIV test where the rate of increase
in optimal adherence was higher for patients who tested due to possible exposure to HIV,
than for patients who tested as they were unwell [aOR=1.046, 95% P=0.021]. Also the rate
of increase in optimal adherence was higher for patients who tested due to possible exposure
to HIV, than for those who reported no specific reason for taking an HIV test [aOR=1.058,
P=0.0339). Age also interacted significantly with gender and education. As the age of
patients increased, females tend to adhere better to HAART than males [aOR: 1.023; 95%,
P=0.009]. Among older patients, those with no schooling were less likely to achieve optimal
HAART adherence than those with secondary and higher education [OR=0.965; 95%,
P=0.014]. As patients got older, those with primary education were more likely to achieve
optimal adherence than those with no schooling [aOR=1.033, P=0.0432].
The conditional independence random-intercept results
The results of a joint conditional independence random-intercepts model showed that the
two random intercepts are significantly negatively associated [ρ = −0.684, P=<0.0001]
(Table 3). This translates into a negative correlation between optimal HAART adherence
and time interval between successive visits, which means that on the overall increasing the
number of days between clinic visits tended to decrease the chances of being optimally
adherent.
Discussion
It is shown that on the overall, optimal HAART adherence is negatively associated with time
interval between successive visits over time. That is, with shorter intervals between one visit
to the next, the patients tend to maintain optimal adherence. Studies have shown that
patients who regularly attend the clinic on scheduled day (or within 2 days) maintain a more
continuous supply of medicines, thus likely to be optimally adherent (Ross-Degnan et al.,
2010). Notwithstanding the negative association between optimal adherence and the time
interval between successive visits, the results further revealed that for a patient with
sustained optimal adherence, the gap between successive clinic visits might be lengthened.
More specifically, the findings highlighted that in the rural treatment site, the patients have
been able to maintain high levels of optimal adherence with longer intervals between
successive visits. Because of staff shortages in the rural treatment site, the time interval
between successive visits was lengthened for the CAT patients with good record of
adherence and our results demonstrates that optimal adherence was not compromised due to
longer intervals between visits. Thus, with the on-going shortage of medical doctors and
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other health workers trained to deliver HIV/AIDS care and treatment in Sub-Saharan Africa
especially in the rural areas (Vasan et al., 2009), our findings provide evidence to suggest
that an ART delivery approach of dispensing longer supplies of medications for patients
who have demonstrated sustained levels of optimal HAART adherence could be adopted.
This might partly help reduce the large numbers of patients that present at the clinics on a
daily basis, especially in situations where health workers are in short supply. The other
advantages of providing patients with longer refills (two or three months rather than the one
month refills) would be the reduced recurrent costs (transport), mean time spent at the clinic
(Hardon et al., 2007).
The results of this study reaffirm the significant determinants of optimal adherence over
time reported by Maqutu et al. (2010a). That is, after accounting for the time interval
measured in days between successive visits, cell phone ownership, living with a partner and
two-way interaction terms that involved time with gender, treatment site and reason for
taking an HIV test, as well as age with gender and educational level were still associated
with optimal adherence. Despite studies consistently showing that demographic
characteristics are generally poor predictors of HAART adherence (Fong et al., 2003), the
results confirm that demographic factors predict HAART adherence through interactions
among themselves or with other variables.
Moreover, it is confirmed that on average, optimal HAART adherence has been increasing
but the rate of increase is higher for females than for males, which could again be
characterized by different social and behavioural factors associated with HAART adherence
among males and females (Berg et al., 2004). In addition, the rate at which optimal
adherence increased over time has been higher in the rural than the urban treatment site,
which has also been observed elsewhere (Birbeck et al., 2009). Furthermore, the results
prove that patients who lived with a partner adhered better to HAART. Lack of social
support has been associated with a decrease in adherence and living with a partner has been
associated with increased social support and optimal adherence (Williams & Friedland,
1997). Also, the results confirm that cell phone ownership enhanced long-term optimal
HAART adherence. This reinforces proposed interventions of providing memory aids for
dosing times that include the use of new technologies such as reminders through cell phones
(Nachega et al., 2007).
This study has some limitations. Firstly, adherence was assessed only through pill counts.
Pill counts method is attractive due to its simplicity and empirical nature; however, it has
disadvantages that include patients not bringing in all their medications or some may empty
(pill dump) their bottles prior to a clinic visit (Bangsberg et al., 2001). Nevertheless, pill
counts have also been shown to be associated with viral load and CD4 count (Bangsberg et
al., 2000). Secondly, interactions between variables were identified using the data and model
fit techniques. The interactions were not pre-specified or expected during data collection.
Detailed information on why these interactions influenced adherence was therefore not
collected, and the reasons for some of these findings cannot be explained.
Our findings provide evidence of a negative association between optimal HAART adherence
and the time interval between successive clinic visits, indicating that the longer the time
interval between successive clinic visits, optimal HAART adherence is likely to be
compromised on the overall. Furthermore, the results confirmed that though optimal
HAART adherence increased over time on average, the rate of increase is low for some sub-
populations, such as the urban and male populations, thus vigorous ongoing adherence
counseling is required.
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Optimal HAART adherence and non-adherence rates over the follow-up visits
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Table 1
Baseline socio-demographic and clinical characteristics of the HAART patients (n = 688)
Characteristic Mean (SD) n (%)
Age (years) 34.1 (8.2)
Gender:
   Men 206 (30%)
   Women 482 (70%)
Education:
   No schooling 74 (12%)
   Primary school 116 (19%)
   Secondary school or higher 429 (69%)
Treatment site:
   Urban 369 (54%)
   Rural 319 (46%)
Living with or without a partner:
   Living with a partner 168 (25%)
   Living without a partner 510 (75%)
Contribution to household income:
   Source of income 186 (28%)
   Not source of income 489 (72%)
WHO stage of HIV disease:
   Stage 1 71 (10%)
   Stage 2 121 (16%)
   Stage 3 438 (64%)
   Stage 4 58 (8%)
Baseline CD4+ count (cells/μL) 107.5 (64.2)
Baseline weight (kg) 61.4 (13.0)
Reason for taking HIV test:
   Unwell 374 (56%)
   No specific reason 170 (26%)
   Possible exposure to HIV 121 (18%)
Household access to tap water:
   Yes 611 (91%)
   No 59 (9%)
Household access to electricity:
   Yes 607 (91%)
   No 63 (9%)
Cell phone ownership:
   Yes 281 (42%)
   No 389 (58%)
First-month optimal HAART adherence:
   Optimally adherent 546 (79%)
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Characteristic Mean (SD) n (%)
   Not optimally adherent 142 (21%)
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Table 2
Adjusted odds ratio (aOR) of a joint marginal model for adherence and time interval outcomes with AR(1)
working covariance structure
Adherence Time interval
Parameter aOR Pvalue aOR Pvalue
Intercept 2.517 0.019 23.831 <.001
Age 0.989 0.161 1.001 0.466
Gender (ref=male)
 Female 0.312 <.001* 1.020 0.649
Education (ref=sec+)
 No schooling 5.629 0.001* 1.085 0.251
 Primary 1.113 0.810 0.987 0.845
Site (ref=rural)
 Urban site 3.320 <.001* 0.996 0.817
Income (ref=source)
 Not source 0.992 0.921 1.013 0.209
Access to tap water (ref=no)
 Yes 1.127 0.309 1.016 0.948
Hhd with electricity (ref=no)
 Yes 0.993 0.948 1.020 0.238
Cell phone ownership (ref=no)
 Yes 1.269 0.001* 1.005 0.585
Reason for HIV test (ref=unwell)
 No specific reason 0.961 0.796 1.004 0.852
 Possible exposure to HIV 0.641 0.011* 0.984 0.396
Staying with a partner (ref=no)
 Yes 1.347 0.002* 1.0003 0.975
WHO staging of HIV (ref=stage4)
 Stage 1 0.715 0.061 1.025 0.310
 Stage 2 0.781 0.125 1.030 0.174
 Stage 3 0.890 0.426 1.023 0.278
Baseline CD4+ cell count 0.999 0.438 1.00004 0.595
Baseline adh (ref=not adherent)
 Adherent 0.858 0.070 0.011 0.251
Time (follow-up visit) 1.107 <.001* 1.013 <.001*
Baseline weight 0.999 0.795 0.001 0.089
Weight at follow-up visits 0.998 0.665 1.002 0.450
Time*gender (ref=male)
 Female 1.074 <.0001* 1.001 0.760
Time*site (ref=rural site)
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Adherence Time interval
Parameter aOR Pvalue aOR Pvalue
 Urban site 0.941 0.0002* 0.993 0.003*
Time*reason for test (ref=unwell)
 No specific reason 0.989 0.560 1.0001 0.965
 Possible exposure to HIV 1.046 0.032* 1.001 0.632
Age*gender (ref=male)
 Female 1.023 0.008* 0.9999 0.914
Age*education (ref=secondary+)
 No schooling 0.965 0.014* 0.998 0.209
 Primary 0.997 0.792 0.9996 0.798
*
Significant at 5% level
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Table 3
Covariance Parameter estimates from the joint conditional independence random intercepts model of the
optimal HAART adherence and time interval outcomes
Variance Components Estimate Standard error Pvalue
Var. R.I (adherence) 0.261 0.062 <0.001
Var. R.I (time interval) 0.005 0.001 <0.001
Correlation between the R.I. (ρ) −0.684 0.139 <0.001
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